Az osteoporosis gyogyszeres kezelesenek ujabb lehetosegei: A biszfoszfonatok es a fluoridok

Translated title of the contribution: New alternatives for the drug therapy in osteoporosis: Bisphosphonates and fluorides

G. Genti, P. Lakatos

Research output: Contribution to journalArticle

Abstract

Bisphosphonates have a potent action on bone: decrease osteoclast- mediated bone resorption, increase bone mineral density, and therefore reduce vertebral fracture rate. Thus, they are an important drug group in the treatment of osteoporosis. Bisphosphonates are particularly useful in postmenopausal osteoporosis, and therefore they can be considered as alternatives for hormone replacement therapy in particular cases. Most clinical experiences are available with the use of cyclical etidronate and daily alendronate, but some early results with other oral bisphosphonates of second and third generations seem to be also promising. Alendronate is the only drug which is proved to increase continuously bone density, and reduce the fracture rate. Data about large group of patients, and long-term studies determining their effect are still required. The side-effect profile of bisphophonates is good, the most common adverse events are gastrointestinal disturbances. The majority of side-effects are related to the failure in following medical recommendations for the administration. Bisphosphonates are the drugs of long-term treatment of osteoporosis. Fluorides have lost their importance since the end of the last decade due to their negative effect on the bone quality. The new fluoride compounds of the latest years increase bone mineral density without altering bone quality. These results indicate the summary of the latest results with fluoride therapy.

Original languageHungarian
Pages (from-to)237-243
Number of pages7
JournalOrvoskepzes
Volume73
Issue number5
Publication statusPublished - 1998

Fingerprint

Diphosphonates
Complementary Therapies
Fluorides
Osteoporosis
Bone Density
Alendronate
Drug Therapy
Bone and Bones
Pharmaceutical Preparations
Etidronic Acid
Postmenopausal Osteoporosis
Hormone Replacement Therapy
Social Justice
Osteoclasts
Bone Resorption
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az osteoporosis gyogyszeres kezelesenek ujabb lehetosegei : A biszfoszfonatok es a fluoridok. / Genti, G.; Lakatos, P.

In: Orvoskepzes, Vol. 73, No. 5, 1998, p. 237-243.

Research output: Contribution to journalArticle

@article{85a52092a8cc4c739e3d3b0f719bfa9c,
title = "Az osteoporosis gyogyszeres kezelesenek ujabb lehetosegei: A biszfoszfonatok es a fluoridok",
abstract = "Bisphosphonates have a potent action on bone: decrease osteoclast- mediated bone resorption, increase bone mineral density, and therefore reduce vertebral fracture rate. Thus, they are an important drug group in the treatment of osteoporosis. Bisphosphonates are particularly useful in postmenopausal osteoporosis, and therefore they can be considered as alternatives for hormone replacement therapy in particular cases. Most clinical experiences are available with the use of cyclical etidronate and daily alendronate, but some early results with other oral bisphosphonates of second and third generations seem to be also promising. Alendronate is the only drug which is proved to increase continuously bone density, and reduce the fracture rate. Data about large group of patients, and long-term studies determining their effect are still required. The side-effect profile of bisphophonates is good, the most common adverse events are gastrointestinal disturbances. The majority of side-effects are related to the failure in following medical recommendations for the administration. Bisphosphonates are the drugs of long-term treatment of osteoporosis. Fluorides have lost their importance since the end of the last decade due to their negative effect on the bone quality. The new fluoride compounds of the latest years increase bone mineral density without altering bone quality. These results indicate the summary of the latest results with fluoride therapy.",
author = "G. Genti and P. Lakatos",
year = "1998",
language = "Hungarian",
volume = "73",
pages = "237--243",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "5",

}

TY - JOUR

T1 - Az osteoporosis gyogyszeres kezelesenek ujabb lehetosegei

T2 - A biszfoszfonatok es a fluoridok

AU - Genti, G.

AU - Lakatos, P.

PY - 1998

Y1 - 1998

N2 - Bisphosphonates have a potent action on bone: decrease osteoclast- mediated bone resorption, increase bone mineral density, and therefore reduce vertebral fracture rate. Thus, they are an important drug group in the treatment of osteoporosis. Bisphosphonates are particularly useful in postmenopausal osteoporosis, and therefore they can be considered as alternatives for hormone replacement therapy in particular cases. Most clinical experiences are available with the use of cyclical etidronate and daily alendronate, but some early results with other oral bisphosphonates of second and third generations seem to be also promising. Alendronate is the only drug which is proved to increase continuously bone density, and reduce the fracture rate. Data about large group of patients, and long-term studies determining their effect are still required. The side-effect profile of bisphophonates is good, the most common adverse events are gastrointestinal disturbances. The majority of side-effects are related to the failure in following medical recommendations for the administration. Bisphosphonates are the drugs of long-term treatment of osteoporosis. Fluorides have lost their importance since the end of the last decade due to their negative effect on the bone quality. The new fluoride compounds of the latest years increase bone mineral density without altering bone quality. These results indicate the summary of the latest results with fluoride therapy.

AB - Bisphosphonates have a potent action on bone: decrease osteoclast- mediated bone resorption, increase bone mineral density, and therefore reduce vertebral fracture rate. Thus, they are an important drug group in the treatment of osteoporosis. Bisphosphonates are particularly useful in postmenopausal osteoporosis, and therefore they can be considered as alternatives for hormone replacement therapy in particular cases. Most clinical experiences are available with the use of cyclical etidronate and daily alendronate, but some early results with other oral bisphosphonates of second and third generations seem to be also promising. Alendronate is the only drug which is proved to increase continuously bone density, and reduce the fracture rate. Data about large group of patients, and long-term studies determining their effect are still required. The side-effect profile of bisphophonates is good, the most common adverse events are gastrointestinal disturbances. The majority of side-effects are related to the failure in following medical recommendations for the administration. Bisphosphonates are the drugs of long-term treatment of osteoporosis. Fluorides have lost their importance since the end of the last decade due to their negative effect on the bone quality. The new fluoride compounds of the latest years increase bone mineral density without altering bone quality. These results indicate the summary of the latest results with fluoride therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032310959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032310959&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032310959

VL - 73

SP - 237

EP - 243

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 5

ER -